Search Results - "Di Lauro, L."

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study by Vici, P., Brandi, M., Giotta, F., Foggi, P., Schittulli, F., Di Lauro, L., Gebbia, N., Massidda, B., Filippelli, G., Giannarelli, D., Di Benedetto, A., Mottolese, M., Colucci, G., Lopez, M.

“…The Gruppo Oncologico Italia Meridionale 9902 trial compared four cycles of high-dose epirubicin plus cyclophosphamide (EC) with four cycles of docetaxel…”
Get full text

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma by DI LAURO, L, NUNZIATA, C, ARENA, M. G, FOGGI, P, SPERDUTI, I, LOPEZ, M

“…This phase II study was designed to evaluate the activity and safety of a combination of irinotecan, docetaxel and oxaliplatin in metastatic gastric or…”
Get full text

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies by Vici, P, Pizzuti, L, Mariani, L, Zampa, G, Santini, D, Di Lauro, L, Gamucci, T, Natoli, C, Marchetti, P, Barba, M, Maugeri-Saccà, M, Sergi, D, Tomao, F, Vizza, E, Di Filippo, S, Paolini, F, Curzio, G, Corrado, G, Michelotti, A, Sanguineti, G, Giordano, A, De Maria, R, Venuti, A

“…Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two…”
Get more information

Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis by Gamucci, T., Vaccaro, A., Ciancola, F., Pizzuti, L., Sperduti, I., Moscetti, L., Longo, F., Fabbri, M. A., Giampaolo, M. A., Mentuccia, L., Di Lauro, L., Vici, P.

“…Purpose Recurrences and deaths are known to occur, even if less frequently, in small, node-negative breast cancer patients, and decision on adjuvant treatments…”
Get full text

M406 HER FAMILY EXPRESSION IN PRENEOPLASTIC LOW AND HIGH-GRADE CERVICAL LESIONS by Mariani, L., Vici, P., Venuti, A., Paolini, F., Vizza, E., Tomao, S., Di Lauro, L., Antoniani, B., Pescarmona, E., Mottolese, M.

Get full text

Machine-Learning Enabled Optimization for Robust Soliton Crystal Generation in Microring Resonators by Mazoukh, C., Lauro, L. Di, Fischer, B., Aadhi, A., Alamgir, I., Eshaghi, A., Little, B. E., Chu, S. T., Moss, D. J., Morandotti, R.

“…We illustrate a novel strategy to robustly generate soliton states in Hydex microring resonators pumped with a continuous-wave laser source, by employing…”
Get full text

Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer by Di Lauro, L., Belli, F., Arena, M. G., Carpano, S., Paoletti, G., Giannarelli, D., Lopez, M.

“…Background: Docetaxel is a new agent with activity in metastatic gastric cancer. This phase II study was designed to evaluate the activity and safety of an…”
Get full text

Analysis of time-delay photonic reservoirs for neuromorphic computing by Dmitriev, P., Di Lauro, L., Fischer, B., Aadhi, A., Chemnitz, M., Viktorov, E., Kovalev, A., Morandotti, R.

“…We numerically investigate time-delay photonic reservoirs to provide a deep understanding of their complex nonlinear dynamics, in connection to their memory…”
Get full text

Specificity of action of anticancer agents by Vici, P, Sergi, D, Pizzuti, L, Vincenzoni, C, Vizza, E, Tomao, F, Morace, N, Toglia, G, Mancini, E, Baiocco, E, Di Lauro, L, Botti, C, Sindico, S, Lopez, M

“…Since the first cancer chemotherapy use, efforts have been made in identifying drugs with an antitumor specific action, but cancer is a very complex situation…”
Get more information

Psyche and cancer by Lopez, M, Cauchi, C, Sergi, D, Amodio, A, Paoletti, G, Vici, P, Di Lauro, L

“…Although the relationship between psyche and cancer dates back many centuries, and several studies were conducted on this topic during the last decades, the…”
Get more information

Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer by Lopez, M, Di Lauro, L, Viola, G, Conti, F, Foggi, P, Vici, P

“…Adjuvant treatment of early breast cancer has changed considerably in recent years, and the majority of patients are currently treated with the most active…”
Get more information

Target selectivity of anticancer drugs by Fattoruso, S I S, Di Lauro, L, Conti, F, Amodio, A, Lopez, M

“…Since the first use of chemotherapy, many efforts were devoted to develop drugs with a specific anticancer activity. Nevertheless, although several approaches…”
Get more information

Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment by Vici, P, Viola, G, Rossi, S, Botti, C, Vitucci, C, Sergi, D, Ferranti, F R, Saracca, E, Di Lauro, L, Corsetti, S, Foggi, P, Fattoruso, S I S, Lopez, M

“…Results from randomized trials evaluating taxane versus non-taxane containing regimens in adjuvant breast cancer treatment indicate an advantage in DFS and OS…”
Get more information

Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients by Vici, P, Viola, G, Botti, C, Rossi, S, Vitucci, C, Corsetti, S, Di Lauro, L, Sergi, D, Foggi, P, Perri, P, Tirelli, C, Mottolese, M, Fattoruso, S I S, Lopez, M

“…Considering the clinical benefit of trastuzumab in advanced breast cancer, fi ve prospective adjuvant randomized trials have recently been completed and early…”
Get more information

A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study by Vici, P, Giotta, F, Di Lauro, L, Sergi, D, Vizza, E, Mariani, L, Latorre, A, Pizzuti, L, D'Amico, C, Giannarelli, D, Colucci, G

“…To evaluate two docetaxel-based regimens as first-line treatment in advanced breast cancer patients. Patients were randomly assigned to docetaxel/gemcitabine…”
Get more information

Development of docetaxel in the adjuvant chemotherapy of breast cancer by Fattoruso, S I S, Rossi, S, Di Lauro, L, Botti, C, Vici, P, Lopez, M

“…The development of taxanes in cancer chemotherapy required several decades of research mainly because of the difficulty related to supply and formulation of…”
Get more information

Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer by Lopez, M, Di Lauro, L, Viola, G, Foggi, P, Conti, F, Corsetti, S, Sergi, D, Botti, C, Di Filippo, F, Vici, P

“…Adjuvant treatment in hormone-receptor positive, HER2-negative early breast cancer is controversial. Chemotherapy benefit in this subset of patients is…”
Get more information

Fiberoptic bronchoscopy as diagnostic tool in primitive lung cancer by Filippetti, M, Visca, P, Bordignon, V, Sergi, D, Marolla, P, Ferretti, G, Tonachella, R, Corzani, F, Fattoruso, S I, Di Lauro, L

“…The aim of this study was to assess the diagnostic role of fiberoptic bronchoscopy in primitive lung cancers in relation to the sensibility, the specificity…”
Get more information

Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer by Fattoruso, S I S, Rossi, S, Vici, P, Di Filippo, F, Botti, C, Di Lauro, L, Foggi, P, Saracca, E, Ferranti, F R, Visca, P, Lopez, M

“…The fundamental imperative of adjuvant treatment of early breast cancer is to improve long-term survival and minimize toxicity. The inclusion of docetaxel in…”
Get more information

Use of nivolumab in elderly patients with advanced non-squamous NSCLC: Results from the Italian expanded access program (EAP) by Migliorino, M.R., Gelibter, A., Grossi, F., Fagnani, D., Bordi, P., Franchina, T., Turci, D., Di Lauro, L., Cascinu, S., Calabro, L., Brighenti, M., Tedde, N., Bearz, A., Giusti, S., Vasile, E., Surico, G., Cartenì, G., Marchetti, P., Verderame, F., Melotti, B.

Get full text